This study is looking at a new treatment called JNJ-78934804 for people with a serious intestine disease called Crohn's disease. Crohn's disease is a condition that makes your intestines inflamed and can get worse over time. The study will compare how well JNJ-78934804 works against another drug called guselkumab over 48 weeks. To join, you need to have Crohn's disease for at least 12 weeks and meet specific activity level criteria. You shouldn't have other types of bowel diseases, certain complications, or surgeries that might affect the study.
- Duration: The study lasts for 48 weeks.
- Eligibility: Must have moderately to severely active Crohn's disease.
- Exclusion: Cannot have other bowel diseases or certain complications.
How understandable was the trial content above?
Hard to understand
Easy to understand